Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-DT-CAR-NK in Advanced Gastric/GEJ Adenocarcinoma
NCT07551362Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of EB-DT-CAR-NK in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by Biotech Pharmaceutical. Primary endpoints: Incidence of dose-limiting toxicities at 28 days, Maximum Tolerated Dose at 6 months and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
EB-DT-CAR-NK
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07551362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551362.